Barclays analyst Matt Miksic says the discontinuation of the Acurate TAVR program at Boston Scientific (BSX) “should not come as a surprise to investors” given the failure to meet its non-inferiority endpoint last year. The firm views the news as “an incremental positive for the stock” as management will reallocate resources to innovative programs with greater potential for higher returns. The firm, which also notes that management reaffirmed its Q2 and 2025 outlook for reported, organic sales, and adjusted EPS, reiterates an Overweight rating and $125 price target on Boston Scientific shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific news ‘zero surprise,’ says JPMorgan
- Citi sees Boston Scientific stopping TAVR valve sales as ‘wise move’
- Boston Scientific’s Strategic Shift and Resilient Outlook: A Buy Rating with 17.7% Expected Return
- Boston Scientific’s Strategic Shift and Growth Potential: A Buy Rating Amid Product Discontinuation and Promising Innovations
- Boston Scientific discontinuing worldwide sales of ACURATE Aortic Valve Systems